SVF
Level D· Preclinical EvidenceAnimal Study

Fibulin-7 in progenitor cells promotes adipose tissue fibrosis and disrupts metabolic homeostasis in obesity.

Yu H., Yang F., Yan D., Chen W., Yao L., Chen H.

Animal Study on Type 2 Diabetes, published in Protein Cell (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Protein Cell (2026)
Country
Germany
Reported sample size
—
PMID
41128612
DOI
10.1093/procel/pwaf084

Abstract (original English)

Fibrosis, resulting from excess extracellular matrix (ECM) deposition, is a feature of adipose tissue (AT) dysfunction and obesity-related insulin resistance. Emerging evidence indicates that adipogenic stem and precursor cells (ASPCs) are a crucial origin of ECM proteins and possess the potential to induce AT fibrosis. Here, we employed single-cell RNA-seq and identified a unique subset of ASPCs that were closely associated with ECM function. Within this subset, we discerned a notable upregulation in the expression of fibulin-7 (FBLN7), a secreted glycoprotein, in obese mice. Similarly, in humans, FBLN7 levels exhibited an increase in visceral fat among obese individuals and demonstrated a correlation with clinical metabolic traits. Functional studies further revealed that, in response to caloric excess, ASPC-specific FBLN7 knockout mice displayed a diminished state of AT fibrosis inflammation, along with improved systemic metabolic health. Notably, the depletion of FBLN7 in ASPCs suppressed TGF-β-induced fibrogenic responses, whereas its overexpression amplified such responses. Mechanistically, FBLN7 interacted with thrombospondin-1 (TSP1) via its EGF-like calcium-binding domain, thereby enhancing the stability of the TSP1 protein. This, in turn, facilitated the conversion of latent TGF-β to its bioactive form, subsequently promoting TGFBR1/Smad signaling pathways. Furthermor

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsObesityFibrosisMiceHumansExtracellular Matrix ProteinsAdipose TissueHomeostasisStem CellsMice, Knockout
Systemic / IVType 2 Diabetes
View on PubMedDOI

Related research